In short
This article examines several clinical trials investigating the use of a recombinant varicella zoster virus glycoprotein E vaccine, known as Shingrix, for preventing shingles (herpes zoster). The trials explore the vaccine's safety, efficacy, and immune response in different patient populations, including kidney transplant recipients, people living with HIV, older adults, and those with psoriasis or psoriatic arthritis. These studies aim to better understand how the vaccine performs in various groups and its potential to prevent shingles and related complications.
What is Shingrix?
Shingrix is a vaccine used to prevent shingles (herpes zoster) in adults. Its active ingredient is a recombinant varicella zoster virus glycoprotein E, which is a protein found on the surface of the varicella zoster virus that causes shingles. Shingrix is manufactured by GlaxoSmithKline Biologicals and is approved for use in many countries, including the European Union and the United States.
How Shingrix Works
Shingrix works by stimulating the body's immune system to produce antibodies and T-cells that can recognize and fight off the varicella zoster virus if you're exposed to it. The vaccine contains a piece of the virus (the glycoprotein E) rather than the whole virus, which allows it to generate an immune response without causing infection.
Who Should Get the Shingrix Vaccine?
Shingrix is recommended for adults aged 50 years and older. It's particularly important for older adults because the risk of developing shingles increases with age. The vaccine is also recommended for people who have previously received the older shingles vaccine (Zostavax) or who have had shingles in the past.
Effectiveness of Shingrix
Clinical trials have shown Shingrix to be highly effective in preventing shingles. Studies indicate that it reduces the risk of developing shingles by more than 90% in adults 50 years and older. The vaccine also helps prevent a painful complication of shingles called postherpetic neuralgia.
Safety and Side Effects
Shingrix is generally considered safe, but like all vaccines, it can cause side effects. The most common side effects include: Pain, redness, and swelling at the injection site Fatigue Muscle pain Headache Shivering Fever Upset stomach These side effects are usually mild to moderate and resolve within a few days.
How Shingrix is Administered
Shingrix is given as two doses, with the second dose administered 2 to 6 months after the first dose. It's important to receive both doses to ensure maximum protection. The vaccine is injected into the muscle, usually in the upper arm.
Use in Special Populations
Research is ongoing to evaluate the safety and effectiveness of Shingrix in various populations. For example, studies are being conducted to assess its use in people with weakened immune systems, such as those who have received organ transplants or are living with HIV.
Ongoing Research
Several clinical trials are currently underway to further investigate Shingrix: A study is examining the vaccine's effectiveness in preventing shingles in kidney transplant patients. Another trial is looking at the immune response to Shingrix in people living with HIV who are over 50 years old. Researchers are also conducting a long-term follow-up study to assess the vaccine's efficacy, safety, and persistence of immune response over time. A study is investigating the safety and immune response of Shingrix in patients with psoriasis or psoriatic arthritis. These ongoing studies will help provide more information about the vaccine's long-term effectiveness and its use in different patient populations.